People with HIV experience earlier impairments in physical function compared to people in the general population. They also exhibit an earlier presentation and more rapid development of frailty, a multisystemic syndrome of aging characterized by reduced activity, fatigue, slowness, weakness, and weight loss. While exercise can improve physical function in people with HIV, it is less effective in doing so than in the general population and is difficult to sustain in the long-term.
The goal of this clinical trial is to learn whether the medication tesamorelin will improve physical function and muscle health in adults with HIV when combined with exercise. Tesamorelin is a growth hormone-releasing hormone analogue that is FDA-approved to treat abdominal fat accumulation in people with HIV. While tesamorelin has also been shown to increase muscle mass and improve measures of muscle health, its effects on physical performance and muscle strength have not yet been evaluated.
During a 24-week intervention phase, half of participants will be randomly assigned to receive tesamorelin and half of participants will be randomly assigned to receive placebo (a look-alike substance that contains no drug). All participants also will engage in a home-based exercise intervention supervised by an exercise coach. During a subsequent 24-week extension phase, individuals will be monitored off study drug and supervised exercise, and be encouraged to continue to exercise independently.
The investigators will investigate effects of tesamorelin on physical function, muscle mass and quality, quality of life, and exercise adherence and self-efficacy. They also will evaluate whether effects of tesamorelin are maintained following treatment cessation. This study may identify an important strategy to improve how individuals aging with HIV function and feel with potential applications to other patient populations.

开始日期2025-03-01

申办/合作机构

The General Hospital Corp.

[+1]

NCT03375788

/ Active, not recruiting临床2期IIT

Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk

Nonalcoholic fatty liver disease (NAFLD) is common in individuals with obesity and is a significant threat to public health, because it can lead to impaired liver function and liver failure. Growth hormone is a hormone produced in the pituitary gland that helps regulate metabolism and growth. Individuals with obesity, on average, secrete less growth hormone than individuals without obesity. There are data to suggest that growth hormone may help to reduce the amount of fat in the liver, and may also reduce inflammation in the liver, both of which would be helpful to individuals with NAFLD. The purpose of this study is to investigate whether treatment with a drug called tesamorelin, which is a growth hormone releasing hormone analogue, will decrease liver fat and improve liver inflammation and scarring in obese individuals with NAFLD.

开始日期2019-01-17

申办/合作机构

The General Hospital Corp.

NCT03226821

/ Recruiting临床4期IIT

Body Composition and Adipose Tissue in HIV Lipodystrophy: Effects of Tesamorelin Therapy

In this study, the investigators will examine the effect of therapy with the Growth Hormone Releasing Hormone (GHRH) analog tesamorelin on body composition in patients with HIV lipodystrophy and central adiposity. This study is a single arm prospective study of tesamorelin therapy of patients with HIV lipodystrophy. Subjects will do body composition testing, adipose tissue biopsy, metabolic rate measurements and insulin sensitivity assessment before, 6 and 12 months after daily injections of tesamorelin 2 mg by subcutaneous injection.

开始日期2018-02-07

申办/合作机构

Columbia University

[+1]

100 项与替莫瑞林相关的临床结果

登录后查看更多信息

100 项与替莫瑞林相关的转化医学

登录后查看更多信息

100 项与替莫瑞林相关的专利（医药）

登录后查看更多信息

104

项与替莫瑞林相关的文献（医药）

2024-10-01·AIDS

Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors

Article

作者: Toribio, Mabel ; Hadigan, Colleen M ; Fourman, Lindsay T. ; Johnson, Julia E. ; Arpante, Allison K. ; Ockene, Mollie W. ; Russo, Samuel C. ; Lee, Hang ; Erlandson, Kristine M ; Johnson, Julia E ; Hadigan, Colleen M. ; Grinspoon, Steven K. ; Stanley, Takara L. ; Arpante, Allison K ; Ockene, Mollie W ; Russo, Samuel C ; Grinspoon, Steven K ; Stanley, Takara L ; Fourman, Lindsay T

Objective:Tesamorelin is the only FDA-approved therapy to treat abdominal fat accumulation in people with HIV (PWH). Phase III clinical trials were conducted prior to the introduction of integrase inhibitors (INSTIs), which are now a mainstay of HIV antiretroviral therapy.Design:We leveraged a randomized double-blind trial of 61 PWH and metabolic dysfunction-associated steatotic liver disease to evaluate the efficacy and safety of tesamorelin 2 mg once daily vs. identical placebo among participants on INSTI-based regimens at baseline.Methods:In the parent clinical trial, visceral fat cross-sectional area, hepatic fat fraction, and trunk-to-appendicular fat ratio were quantified using magnetic resonance imaging, proton magnetic resonance spectroscopy, and dual-energy x-ray absorptiometry, respectively, at baseline and 12 months. Metabolic and safety outcomes were compared between treatment arms.Results:Among 38 participants on INSTI-based regimens at baseline, 15 individuals on tesamorelin and 16 individuals on placebo completed the 12-month study. Tesamorelin led to significant declines in visceral fat (median [interquartile range]: −25 [−93, −2] vs. 14 [3, 41] cm2, P = 0.001), hepatic fat (−4.2% [−12.3%, −2.7%] vs. −0.5% [−3.9%, 2.7%], P = 0.01), and trunk-to-appendicular fat ratio (−0.1 [−0.3, 0.0] vs. 0.0 [−0.1, 0.1], P = 0.03). Tesamorelin was well tolerated with a similar frequency of adverse events, including hyperglycemia, between groups.Conclusions:The current analysis provides the first dedicated data on the efficacy and safety of tesamorelin among PWH on INSTI-based regimens. Despite the association of INSTI use with weight gain and adipose tissue dysfunction, tesamorelin had beneficial effects on body composition with no exacerbation of glycemic control.

2024-08-12·Topics in antiviral medicine

CROI 2024: Neuropsychiatric Complications in People With HIV.

Review

作者: Letendre, Scott L ; Corley, Michael J ; Nightingale, Sam

The 2024 Conference on Retroviruses and Opportunistic Infections featured new and impactful findings about neuropsychiatric complications in people with HIV and other infections. Reports included new evidence from low- and middleincome countries, HIV persistence in the central nervous system, aging-related complications (including cerebrovascular disease), additional data relevant to pathogenesis, and therapeutics. Also included were new evidence of active HIV RNA transcription in cells from cerebrospinal fluid and the brain during virally suppressive antiretroviral therapy as well as links between neuropsychiatric complications or brain imaging findings in people with HIV and a) carotid artery inflammation and cerebrovascular disease, b) Alzheimer's disease genetic risk, c) social determinants of health, including exposure to pollution, and d) epigenetic aging. New therapeutic findings were presented on the cerebrospinal fluid inhibitory quotient, the effects of polypharmacy, and clinical trials of tesamorelin and telmisartan. This review summarizes these and other new findings and highlights new research directions for the neuro-HIV field.

2023-12-01·Analytical biochemistry

Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.

Article

作者: David, Victor ; Cristea, Cătălina-Diana ; Radu, Mihai ; Toboc, Ani ; Stan, Cristina

The use of growth hormone-releasing hormones (GHRHs) is prohibited in sports according to the regulations of the World Anti-Doping Agency (WADA). Considering the complexity of urine samples and the low concentrations at which these analytes should be detected, analyzing GHRHs is a challenging task. In most of the studies, GHRHs are analyzed using UHPLC-HRMS with an orbitrap. The present developed and validated method for some GHRHs (tesamorelin, CJC-1295, sermorelin (GRF 1-29), sermorelin (3-29)-NH₂, somatorelin) is based on the triple quadrupole UHPLC/MS-MS method with solid phase extraction (SPE) with weak cation exchange and is able to detect concentrations as low as 0.2 ng/mL (LOD), a limit of quantification (LOQ) at 0.6 ng/mL, and linearity across the range of 0.1 ng/mL to 1.2 ng/mL. The present method developed by our doping control laboratory was validated according to WADA technical documents for selectivity, limit of detection (LOD), carryover, reliability of detection, stability and recovery. The results show that the method has adequate recoveries and sensitivity, hence, it can be employed for routine screening in anti-doping laboratories.

项与替莫瑞林相关的新闻（医药）

2025-03-10

·药时空

GSK、Alnylam、赛诺菲等药企3月迎FDA大考，哪些新药有望获批？

3月对美国食品药品监督管理局（FDA）来说是一个繁忙的月份，近十种药物的审批决策日期集中在本月，覆盖了多种疾病领域。本月备受期待的审批结果包括新一代抗生素用于治疗尿路感染，以及两种RNA干扰（RNAi）疗法。以下是详细内容：1.Scienture有望获批首个洛沙坦口服液 Scienture正在推进一种洛沙坦的口服液制剂，FDA的审批决策日期定于3月17日。洛沙坦是一种广受欢迎的降压药，该公司的新药申请（NDA）名为SCN-102，旨在用于治疗成人和6岁及以上儿童的高血压，以降低血压。此外，该药物还被提议用于降低伴有左心室肥厚的高血压患者中风的可能性，以及治疗2型糖尿病患者的糖尿病肾病。为支持其申请，Scienture提交了SCN-102的I期药代动力学数据，显示该口服液在洛沙坦暴露量方面与速释片剂“相当接近”。此外，与洛沙坦片剂相比，SCN-102达到峰值浓度的时间更早，这是由于其口服液的剂型所致，公司文件中也提到这一点。如果获批，SCN-102将成为首个上市的洛沙坦口服液。2.Elevar的肝癌一线治疗方案待审批 3月20日，FDA将公布对ElevarTherapeutics的VEGF酪氨酸激酶抑制剂rivoceranib的审批结果。该公司提议将该药物与PD-1抑制剂卡瑞利珠单抗联合，用于不可切除或转移性肝细胞癌的一线治疗。 rivoceranib的数据包包括III期CARES-310试验的结果，该试验在2024年5月公布，显示rivoceranib组合的中位总生存期显著长于索拉非尼单独治疗。研究还指出，在接受卡瑞利珠单抗加rivoceranib治疗的患者中，无进展生存期、治疗反应和反应持续时间都有益处。 Elevar在2023年首次尝试为rivoceranib争取获批，但2024年5月被拒。FDA在完全回应函中指出，问题出在第三方供应商的生产问题上，以及由于FDA旅行限制导致的临床现场检查不完整。Elevar在2024年9月重新提交了申请。3.Alnylam的RNAi疗法ATTR-CM扩展标签审批在即本月最受期待的FDA决策之一是AlnylamPharmaceuticals的RNAi疗法vutrisiran，FDA的审批决策日期为3月23日。Alnylam正在寻求将该药物的标签扩展到包括转甲状腺素蛋白淀粉样变性（ATTR）伴心肌病的治疗。该药物以商品名Amvuttra获批，但目前仅限于治疗遗传性ATTR的多发性神经病。该药物通过靶向并敲低转甲状腺素蛋白RNA的野生型和突变型，降低蛋白质的表达。根据Alnylam的说法，这种作用机制使vutrisiran能够解决ATTR及其心肌病表现的潜在病理级联反应。 Alnylam申请标签扩展的依据是HELIOS-B研究的数据，该研究结果于2024年8月发表在《新英格兰医学杂志》上。结果显示，经过vutrisiran治疗后，全因死亡风险降低了28%，复发性心血管事件风险降低了33%。如果获批，vutrisiran将成为首个获批用于治疗ATTR的多发性神经病和心肌病表现的药物。4.Theratechnologies再次提交HIV脂代谢异常药物的申请在去年遭到拒绝后，Theratechnologies正在等待FDA对其F8型号的tesamorelin的审批结果，预计决策日期为3月25日。这是一种肽疗法，该公司提议用于减少HIV患者和脂代谢异常人群的腹部脂肪。在完全回应函中，FDA指出了与tesamorelin的化学、生产和控制相关的问题，特别是杂质和药物稳定性问题。在2024年11月重新提交的申请中，Theratechnologies表示已解决FDA的担忧，并提供了有关tesamorelin免疫原性风险的额外数据。 Tesamorelin通过模拟生长激素释放因子，促进生长激素的分泌，进而促进腹部脂肪的分解。该药物于2010年首次获批，F4型号（浓度是原始产品的四倍）于2018年获批。此次药物申请寻求批准的型号是原始产品的八倍浓度。5.GSK推出首类抗生素治疗无并发症尿路感染到3月26日，FDA将公布对GSK的新型抗生素gepotidacin的审批结果，该药物用于治疗成年女性和体重至少40公斤的12岁及以上青少年的无并发症尿路感染。 Gepotidacin是一种首类三氮杂并萘烯抗生素，通过靶向并阻止细菌DNA的复制来发挥作用，其作用机制独特。由于gepotidacin采用了一种新的机制来靶向细菌，因此它对大多数尿路病原体（如大肠杆菌和腐生葡萄球菌）以及耐药菌株（包括淋病奈瑟菌）均显示出活性。 GSK以III期EAGLE-2和EAGLE-3研究的数据支持其申请，这些研究在2023年4月发现gepotidacin与当前一线治疗药物呋喃妥因相比具有非劣效性。例如，EAGLE-2研究显示，接受gepotidacin治疗的患者治疗成功率为50.6%，而呋喃妥因组为47%。EAGLE-3研究中，两组的成功率分别为58.5%和43.6%。6.Milestone推出心动过速鼻喷雾剂 MilestonePharmaceuticals的主要管线资产是Cardamyst，这是一种用于治疗阵发性室上性心动过速（PSVT）的etripamil鼻喷雾剂，FDA预计将在3月27日公布审批结果。 2023年10月，当FDA接受Milestone的首个Cardamyst新药申请时，该公司表示已提交了“在PSVT研究中规模最大的数据包”。当时，公司提交的所谓“全面数据包”表明，其研究性钙通道阻滞剂在恢复正常心律方面“是安慰剂的两倍有效，速度是安慰剂的三倍”。然而，尽管有广泛的证据基础，FDA在2023年12月以拒绝受理信的形式驳回了Milestone的申请，理由是该公司提交的文件不足以进行完整的审查。Milestone在2024年3月重新提交了申请，FDA在同年5月接受了该申请。7.Soleno的普拉德-威利综合征药物审批在即 FDA计划在3月27日公布对SolenoTherapeutics的普拉德-威利综合征（PWS）药物氯化二氮卓的审批结果。 Soleno的氯化二氮卓是一种氯化二氮卓的缓释制剂，这种分子长期以来一直被用于治疗各种罕见疾病，但尚未获批用于PWS。根据Soleno的说法，该公司在2024年6月提交的药物申请得到了III期数据的支持，这些数据表明该候选药物有潜力解决PWS的关键症状，包括食欲亢进、攻击性行为和脂肪堆积。 Soleno还提交了五项I期健康志愿者研究和三项III期试验的结果。2024年11月，该公司宣布FDA需要更多时间来审查其氯化二氮卓的申请，特别是在公司回应某些信息请求后。监管机构将这些额外提交视为药物申请的重大修订，并将截止日期推迟了三个月。8.Sanofi和Alnylam寄望血友病RNAi疗法获批 Alnylam在这份名单上的第二次出现是其与Sanofi合作的siRNA疗法fitusiran，预计FDA的审批决策日期为3月28日。这两家公司提议将该药物用于治疗血友病A和B。为支持这种RNAi疗法，Sanofi和Alnylam进行了ATLAS临床开发计划，该计划的出版物于2023年4月发表在《柳叶刀》和《柳叶刀血液学》上。在一项名为ATLAS-INH的研究中，fitusiran治疗使66%的同时接受因子VIII抑制剂治疗的患者每月出血次数为零。另一项名为ATLASA/B的研究发现，在没有抑制剂的患者中，51%的患者在fitusiran治疗后每月出血次数为零。 Fitusiran通过皮下注射给药，通过靶向并降低抗凝血酶的表达来发挥作用，抗凝血酶是一种抑制凝血的蛋白。识别微信二维码，可添加药时空小编请注明：姓名+研究方向！

临床3期申请上市临床2期临床结果加速审批

2025-02-14

·GlobeNewswire-Health Care

Theratechnologies Resumes Distribution of EGRIFTA SV®

MONTREAL, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care, today announced that it has resumed distribution of EGRIFTA SV® (tesamorelin for injection), following correspondence from the U.S. Food and Drug Administration (FDA) that allows the Company to release two recently manufactured batches of EGRIFTA SV®. The product is ready for immediate shipment to network pharmacies. “We remain committed to providing EGRIFTA SV® to people with HIV and we truly appreciate the FDA’s collaboration to get the treatment back to the patients who rely on it,” said Christian Marsolais, PhD, Senior Vice President and Chief Medical Officer at Theratechnologies. Review of the Company’s Prior Approval Supplement by the FDA is ongoing with an action goal date of April 18, 2025. EGRIFTA SV® is distributed in the United States only. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and X. Forward-Looking Information This press release contains forward-looking statements and forward-looking information (collectively, the “Forward-Looking Statements”) within the meaning of applicable securities laws, that are based on management’s beliefs and assumptions and on information currently available to it. You can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “promising”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate”, or the negatives of these terms, or variations of them. The Forward-Looking Statements contained in this press release include, but are not limited to, statements regarding: (i) the review of the Prior Approval Supplement (PAS) within the timelines announced herein; and (ii) the provision of EGRIFTA SV® to people with HIV. Although the Forward-Looking Statements contained in this press release are based upon what the Company believes are reasonable assumptions in light of the information currently available, investors are cautioned against placing undue reliance on these statements since actual results may vary from the Forward-Looking Statements contained in this press release. Certain assumptions made in preparing the Forward-Looking Statements include that: (i) the PAS will be approved by the FDA; (ii) the review of the PAS will be completed within the timelines disclosed herein; (iii) current market demand for EGRIFTA SV® has not been adversely impacted by the drug shortage; and (iv) the Company’s third party manufacturer will be able to continue the manufacture of EGRIFTA SV® to meet patients demand . Forward-Looking Statements assumptions are subject to a number of risks and uncertainties, many of which are beyond the Company’s control, that could cause actual results to differ materially from those that are disclosed in or implied by such Forward-Looking Statements. These risks and uncertainties include, but are not limited to: (i) FDA’s review of the PAS not being completed by April 18, 2025; (ii) non-approval of the PAS; (iii) issuance of questions as part of the PAS review by the FDA resulting in delays in completing the PAS review and resulting in delays beyond April 18, 2025, to release additional batches of EGRIFTA SV®, if need be; (iv) issuance of a complete response letter following the filing of the PAS as a result of the manufacturing site being classified as Official Action Indicated preventing the Company from releasing additional batches of EGRIFTA SV®, unless new authorizations similar to the one announced herein are obtained from the FDA; and (v) a decrease in demand for EGRIFTA SV® due to the recent shortage adversely impacting the resumption of the commercialization of EGRIFTA SV®;. The Company refers current and potential investors to the “Risk Factors” section of the Company’s Form 20-F dated February 21, 2024 available on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov under Theratechnologies’ public filings. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-Looking Statements reflect current expectations regarding future events and speak only as of the date of this press release and represent the Company’s expectations as of that date. The Company undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law. Contacts: Media inquiries:Julie SchneidermanSenior Director, Communications & Corporate Affairscommunications@theratech.com1-514-336-7800 Investor inquiries:Joanne ChoiSenior Director, Investor Relationsjchoi@theratech.com1-551-261-0401

上市批准

2025-01-10

·GlobeNewswire-Health Care

World Orphan Drug Alliance expands to Canada and full LATAM region, completing the first truly global commercialization offering

By adding Canada and the entire Latin America region, including Mexico, WODA completes its full global commercialization offering for rare and specialty therapies.With two new members - Innovative Medicines Group and Theratechnologies - WODA now provides access to over 210 million rare disease patients. MONTREAL and MONTEVIDEO, Uruguay, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The World Orphan Drug Alliance (WODA), a global alliance of commercial distributors dedicated to providing access to treatments for rare diseases and specialty medicines in complex markets worldwide, has expanded its reach to include Canada and all of Latin America (LATAM). The addition of two new members - Theratechnologies Inc. for Canada and Innovative Medicines Group (IMG) for LATAM - brings the total number of countries covered by WODA to 158 and extends its reach to 210 million rare disease patients. The alliance now consists of 12 members, each being expert for the region covered. This expansion effectively completes WODA's ambition to provide global access to rare disease treatments. “With a new partner in LATAM and the addition of Canada, we are thrilled to become the only truly global-for-local platform," said Patrick Jordan, Chairman of WODA. "Canada not only gives our partners a footprint in North America, but with Theratechnologies’ operations in the U.S., they can be a U.S. solution as well. With IMG, we have a broader coverage of LATAM, including Mexico." Headquartered in Montreal, Theratechnologies was one of WODA’s first partners with the distribution of EGRIFTA SV® globally. They have recently broadened their portfolio, announcing an exclusive licensing deal with Ionis Pharmaceuticals for two assets in Canada. With a strong history of collaboration, Theratechnologies is a natural partner for WODA in Canada. WODA has also gained a strong new member in IMG, introducing a new platform for LATAM. IMG allows for a turnkey solution in the stalwart markets of Brazil, Argentina, and Colombia, and with a strong regional footprint ensures coverage across the rest of Latin America, including Mexico. Based in Montevideo, Uruguay, the team has a proven track record of serving rare disease patients throughout the region. The Alliance now provides a broad outreach with a local focus through thirteen separate entities: Specialised Therapeutics (Australia, New Zealand and Southeast Asia), Medis (Central and Eastern Europe & Nordics), Path Pharma (Greece, Cyprus, Malta), CTS (Israel), Innovative Medicines Group (Latin America), Vector Pharma (Middle East, North Africa, and Turkey), Orpharm (Russia and the CIS region), EffRx (Switzerland), Veld (Africa), Nxera (Japan, South Korea), Theratechnologies (Canada) and its boutique consultancy partner Decisive Consulting. About WODAThe World Orphan Drug Alliance (WODA) is a global alliance of commercial distributors focused on providing access to treatments for rare diseases and specialty medicines in complex markets around the world. WODA aims to provide comprehensive support to pharmaceutical and biotech companies with rare disease, oncology, and highly specialized therapeutics portfolio, starting from Named Patient Programs through to full commercialization. More about WODA: www.woda-alliance.com Media contact: Tina Vojnovic, tina.vojnovic@woda-alliance.com+386 41 744 735

引进/卖出孤儿药

100 项与替莫瑞林相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	替莫瑞林	H01AC06	DB08869

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
HIV感染	美国	Theratechnologies, Inc.	2010-11-10
脂肪营养不良	美国	Theratechnologies, Inc.	2010-11-10

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肝纤维化	临床2期	加拿大	Theratechnologies Europe Ltd.	2022-01-30
肌肉萎缩	临床前	-	Theratechnologies, Inc.	2011-09-01
慢性阻塞性肺疾病	临床前	-	Theratechnologies, Inc.	2011-09-01
HIV血清阳性	药物发现	加拿大	Theratechnologies, Inc.	2008-05-01
HIV相关性脂肪营养不良综合征	药物发现	美国	Theratechnologies, Inc.	2005-06-01
HIV相关性脂肪营养不良综合征	药物发现	加拿大	Theratechnologies, Inc.	2005-06-01
2型糖尿病	药物发现	-	Theratechnologies, Inc.	2002-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


GlobeNewswire 人工标引	临床3期	心血管疾病 \| HIV感染	-	Tesamorelin	製鹽顧範蓋壓襯鏇餘憲(夢艱鹽鹹觸網憲餘鏇鑰) = 衊獵觸製積衊齋遞遞簾夢觸窪艱鏇觸簾範願願 (廠衊膚鹹繭壓糧衊繭觸, -0.89 ~ 0.05)	积极	2024-10-17
ENDO2021	N/A	代谢功能障碍相关的脂肪肝病维持 C-C Motif Chemokine Ligands 3 \| interleukin-8 \| interleukin-10 ... 更多	61	Tesamorelin	膚壓夢鏇醖鹽遞鏇襯廠(願觸顧鹽遞範構醖範構) = 鬱鏇構選繭壓鏇鏇選衊窪選窪廠廠糧齋構範衊 (齋鏇願獵鑰鑰獵衊夢艱 ) 更多	积极	2021-05-03
NCT02196831 (CTgov)	N/A	非酒精性脂肪性肝炎 \| HIV感染	61	tesamorelin (Tesamorelin)	廠願繭築獵膚製艱積襯(範廠壓廠餘觸窪觸壓糧) = 壓鏇鑰淵選膚鹽願網鏇壓遞窪鹹憲夢窪淵鹹齋 (選獵網襯膚窪鹹壓襯繭, 憲網鬱鹹繭憲衊蓋壓簾 ~ 簾遞繭餘襯廠廠蓋積鬱) 更多	-	2020-01-13
				Placebo (Placebo)	廠願繭築獵膚製艱積襯(範廠壓廠餘觸窪觸壓糧) = 顧襯襯壓窪壓獵餘壓繭壓遞窪鹹憲夢窪淵鹹齋 (選獵網襯膚窪鹹壓襯繭, 蓋積鹽衊構網廠積餘築 ~ 觸膚衊壓鬱糧鬱鬱獵鑰) 更多
NCT00608023 \| NCT00123253 (Pubmed)	临床3期	HIV感染	806	Tesamorelin	(襯夢齋醖淵衊襯襯選範) = 蓋簾獵衊選積鹽願鹽選夢鑰積鑰鑰廠蓋夢憲鑰 (範鏇獵鏇窪獵範鹽網願 ) 更多	-	2017-10-23
				Placebo	(襯夢齋醖淵衊襯襯選範) = 範簾構簾鬱艱鹽製襯遞夢鑰積鑰鑰廠蓋夢憲鑰 (範鏇獵鏇窪獵範鹽網願 ) 更多
NCT00807365 (PP2, CTgov)	临床2期	-	5	GHRH	製築艱選壓壓鬱醖願廠(齋簾網鹽蓋廠繭鑰膚願) = 鹽繭窪構築願襯壓選鑰築築鹽憲蓋願夢醖獵範 (鹽艱鑰網淵膚鏇鑰衊顧, 淵衊願簾醖糧簾簾繭艱 ~ 獵蓋範醖網艱製築鹹蓋) 更多	-	2017-04-27
NCT01263717 (CTgov)	N/A	HIV相关性脂肪营养不良综合征	54	tesamorelin (Tesamorelin)	膚鹹製鹽鹽製積醖餘淵(鹹簾餘鏇膚鏇醖夢醖襯) = 膚繭遞鬱淵獵淵窪鏇製製窪淵獵窪鹹繭夢遞糧 (選製餘範齋鑰襯壓餘獵, 糧繭構憲衊廠遞鏇糧遞 ~ 窪獵鹽壓範餘淵鏇遞觸) 更多	-	2014-10-13
				placebo (Placebo (Inactive Injection))	膚鹹製鹽鹽製積醖餘淵(鹹簾餘鏇膚鏇醖夢醖襯) = 鑰網夢鹽選願壓壓顧鏇製窪淵獵窪鹹繭夢遞糧 (選製餘範齋鑰襯壓餘獵, 範願艱廠鹽糧遞夢鏇餘 ~ 鹽選鏇遞鹽艱淵構糧憲) 更多
NCT01263717 (Pubmed \| JAMA)	N/A	HIV感染	50	Tesamorelin 2 mg	憲淵選衊鏇鹹範窪獵願(襯構遞窪襯襯築醖廠艱) = 願淵壓築蓋壓製齋製鏇積顧餘構淵餘窪蓋網齋 (網膚餘憲網築憲鹽壓構 ) 更多	-	2014-07-30
				Placebo	憲淵選衊鏇鹹範窪獵願(襯構遞窪襯襯築醖廠艱) = 鑰夢廠齋遞憲顧鏇簾觸積顧餘構淵餘窪蓋網齋 (網膚餘憲網築憲鹽壓構 ) 更多
NCT01388920 (CTgov)	临床2期	慢性阻塞性肺疾病 \| 肌肉萎缩	3	Tesamorelin (Tesamorelin 2 mg)	艱鬱顧鏇網鹽鑰廠餘願(積範積淵觸鑰鑰構餘膚) = 繭簾艱製獵鬱壓遞選艱鏇艱遞顧鑰鹹範製願膚 (餘夢廠壓窪網餘艱鬱積, 膚繭願製夢遞夢鏇顧齋 ~ 憲築艱糧膚觸憲觸鹽襯) 更多	-	2014-05-07
				Tesamorelin (Tesamorelin 3 mg)	艱鬱顧鏇網鹽鑰廠餘願(積範積淵觸鑰鑰構餘膚) = 蓋願簾觸衊鹽鏇衊淵選鏇艱遞顧鑰鹹範製願膚 (餘夢廠壓窪網餘艱鬱積, 鏇鬱範襯餘壓製艱構觸 ~ 衊廠鹹遞構糧構範願鏇) 更多
NCT00795210 (CTgov)	N/A	脂肪营养不良 \| HIV感染	25	growth hormone (GH 6mcg/kg/d)	鏇壓膚衊壓淵醖窪壓襯(獵遞蓋獵鏇壓鏇選憲艱) = 淵繭遞憲醖壓鹽製獵範繭壓簾選鏇憲壓選餘膚 (鬱遞衊構願鹹鏇積糧鹹, 廠鹽範獵繭壓衊築糧繭 ~ 窪艱觸蓋顧齋構顧獵製) 更多	-	2014-01-08
				growth hormone (GH 2mg Daily)	鏇壓膚衊壓淵醖窪壓襯(獵遞蓋獵鏇壓鏇選憲艱) = 鹽憲鑰襯壓衊顧鏇餘選繭壓簾選鏇憲壓選餘膚 (鬱遞衊構願鹹鏇積糧鹹, 膚選窪遞顧積蓋餘願顧 ~ 鏇蓋鏇齋餘膚壓壓網醖) 更多